
Entrada Therapeutics (TRDA) Stock Forecast & Price Target
Entrada Therapeutics (TRDA) Analyst Ratings
Bulls say
Entrada Therapeutics is poised for success in the biopharmaceutical market with its innovative Endosomal Escape Vehicle (EEV)-therapeutics, which have the potential to unlock previously inaccessible intracellular targets and treat a variety of diseases. The company's partnership with Vertex Pharmaceuticals to develop a treatment for myotonic dystrophy type 1 (DM1) is a strong indicator of the potential success of the platform. With ongoing trials progressing well and a potential for accelerated approval in the US, this stock is a strong buy with a price target of $20.
Bears say
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Endosomal Escape Vehicle (EEV)-therapeutics. Although the company has partnered with Vertex Pharmaceuticals for a clinical-stage program for myotonic dystrophy type 1, the efficacy data for their oligonucleotide programs is concerning as it shows a lower splicing index reduction compared to competitors. Additionally, their financials show high capital expenditures with little revenue, making their future prospects uncertain.
This aggregate rating is based on analysts' research of Entrada Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Entrada Therapeutics (TRDA) Analyst Forecast & Price Prediction
Start investing in Entrada Therapeutics (TRDA)
Order type
Buy in
Order amount
Est. shares
0 shares